Mesoblast (MESO) Income towards Parent Company (2015 - 2025)
Mesoblast recorded quarterly Income towards Parent Company of -$40.2 million in Q4 2025, up 16.21% quarter-over-quarter from -$47.9 million in Q2 2025, and up 16.21% year-over-year from -$34.6 million in Q4 2024.
Mesoblast's Income towards Parent Company history runs 11 years deep, the most recent figure standing at -$40.2 million for Q4 2025.
- In Q4 2025, Income towards Parent Company rose 16.21% year-over-year to -$40.2 million; the TTM figure through Dec 2025 stood at -$168.6 million (down 9.19% YoY), while the FY2025 annual figure was -$102.1 million, down 16.13% from the prior year.
- Income towards Parent Company came in at -$40.2 million for Q4 2025 at Mesoblast, up from -$47.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $25.9 million in Q4 2021 to a low of -$76.8 million in Q1 2021.
- A 5-year average of -$32.3 million and a median of -$32.5 million in 2023 frame the typical range for Income towards Parent Company.
- On a YoY basis, Income towards Parent Company climbed as much as 151.65% in 2021 and fell as far as 602.86% in 2021.
- Mesoblast's Income towards Parent Company stood at $25.9 million in 2021, then retreated by 5.62% to $24.5 million in 2022, then plunged by 232.89% to -$32.5 million in 2023, then plunged by 47.31% to -$47.9 million in 2024, then increased by 16.21% to -$40.2 million in 2025.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$40.2 million, -$47.9 million, and -$47.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -40.16 Mn |
| Jun 30, 2025 | -47.93 Mn |
| Dec 31, 2024 | -47.93 Mn |
| Jun 30, 2024 | -32.54 Mn |
| Dec 31, 2023 | -32.54 Mn |
| Jun 30, 2023 | -41.37 Mn |
| Mar 31, 2023 | -59.97 Mn |
| Dec 31, 2022 | 24.49 Mn |
| Sep 30, 2022 | -16.88 Mn |
| Jun 30, 2022 | -69.89 Mn |
| Mar 31, 2022 | -21.39 Mn |
| Dec 31, 2021 | 25.95 Mn |
| Sep 30, 2021 | -22.65 Mn |
| Jun 30, 2021 | -24.54 Mn |
| Mar 31, 2021 | -76.75 Mn |
| Dec 31, 2020 | -50.24 Mn |
| Sep 30, 2020 | -24.54 Mn |
| Jun 30, 2020 | -45.33 Mn |
| Mar 31, 2020 | 15.26 Mn |
| Dec 31, 2019 | 24.58 Mn |
| Sep 30, 2019 | -5.48 Mn |
| Jun 30, 2019 | -69.07 Mn |
| Mar 31, 2019 | 24.97 Mn |
| Dec 31, 2018 | 24.60 Mn |
| Sep 30, 2018 | -19.50 Mn |
| Jun 30, 2018 | -20.83 Mn |
| Mar 31, 2018 | 21.14 Mn |
| Dec 31, 2017 | 13.70 Mn |
| Sep 30, 2017 | -7.02 Mn |
| Jun 30, 2017 | -27.18 Mn |
| Mar 31, 2017 | -9.78 Mn |
| Dec 31, 2016 | -20.05 Mn |
| Sep 30, 2016 | -19.80 Mn |
| Jun 30, 2016 | -116.72 Mn |
| Mar 31, 2016 | -21.12 Mn |
| Dec 31, 2015 | -22.33 Mn |